What-do-i-need-to-know

INFORMATION FOR REPATHA® (EVOLOCUMAB) PATIENTS

What do I need to know before I start Repatha® (evolocumab)?1

Do not use Repatha® if you are allergic to evolocumab or any of the other ingredients of this medicine. The other ingredients are: proline, glacial acetic acid, polysorbate 80, sodium hydroxide and water for injections
For further information, please refer to section 6 of the Patient Information Leaflet.
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Repatha® if you have liver disease.
The needle cover of the glass pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.
Children and adolescents The use of Repatha® has not been studied in children under 18 years of age being treated for primary hypercholesterolaemia and mixed dyslipidaema.
The use of Repatha® has not been studied in children under 12 years of age being treated for homozygous familial hypercholesterolaemia.
Other medicines and Repatha® Tell your doctor or pharmacist if you are taking, have recently taken, or might take, any other medicines.
Pregnancy and breastfeeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Repatha® has not been tested in pregnant women. It is not known if Repatha® will harm your unborn baby. It is not known whether Repatha® is found in breast milk.
It is important to tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding, or whether to stop taking Repatha®, considering the benefit of breast-feeding to the baby and the benefit of Repatha® to the mother.
Driving and using machines Repatha® has no or negligible influence on the ability to drive and use machines.
Repatha® contains sodium This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.
References
  1. Repatha® Summary of Product Characteristics.

This site is intended for patients in Ireland who are being treated with an Amgen® product and for Irish Healthcare Professionals (HCPs).

I am a member of the public
IE-CBU-0820-00002 August 2020